Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
VitriVax Raises $17.25M Series B to Advance Thermostable Vaccine Technology
Series BVenture Capital

VitriVax Raises $17.25M Series B to Advance Thermostable Vaccine Technology

•October 22, 2025
•Oct 22, 2025
0

Participants

VitriVax

VitriVax

company

Adjuvant Capital

Adjuvant Capital

investor

RA Capital

RA Capital

investor

Deal Summary

VitriVax, a Boulder-based vaccine formulation technology company, raised $17.25M in a Series B round co-led by Adjuvant Capital and RA Capital Management to fund development and commercialization of its ALTA® thermostable antigen and adjuvant technology. Proceeds will support continued product development and commercialization efforts.

0

Comments

Want to join the conversation?

Loading comments...